Fig. 10: Per-gene actionable events catalogued by OncoKB.
From: Genomic landscape of diffuse glioma revealed by whole genome sequencing
Level 1: FDA-recognised biomarker predictive of response to an FDA-approved drug in this indication; Level 2: Standard care biomarker predictive of a response to an FDA-approved drug in this indication; Level 3A: Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication; Level 3B: Standard care or investigational biomarker predictive of response to an FDA-approved or investigational drug in another indication; Level 4: Compelling biological evidence supports the biomarker as being predictive of response to a drug. A Primary GBM; B recurrent GBM; C primary astrocytoma; D recurrent astrocytoma; E primary oligodendroglioma; F recurrent oligodendroglioma.
